Last reviewed · How we verify

Diclofenac hydroxyethylpyrrolidine — Competitive Intelligence Brief

Diclofenac hydroxyethylpyrrolidine (Diclofenac hydroxyethylpyrrolidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal anti-inflammatory drug (NSAID). Area: Pain management, Rheumatology, Inflammation.

marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain management, Rheumatology, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Diclofenac hydroxyethylpyrrolidine (Diclofenac hydroxyethylpyrrolidine) — IBSA Institut Biochimique SA. Diclofenac hydroxyethylpyrrolidine is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diclofenac hydroxyethylpyrrolidine TARGET Diclofenac hydroxyethylpyrrolidine IBSA Institut Biochimique SA marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
NSAID therapy NSAID therapy Rabin Medical Center marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Oral tablets of Alphintern® Oral tablets of Alphintern® Ain Shams University marketed Non-steroidal anti-inflammatory drug (NSAID) COX-2
NSAID (Ketorolac/Ibuprofen) NSAID (Ketorolac/Ibuprofen) Thomas Jefferson University marketed Non-steroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
Tinoridine HCl Tinoridine HCl Takeda marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Metamizole Sodium Metamizole Sodium Insel Gruppe AG, University Hospital Bern marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
NSAID's NSAID's Saglik Bilimleri Universitesi Gulhane Tip Fakultesi marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal anti-inflammatory drug (NSAID) class)

  1. Ain Shams University · 1 drug in this class
  2. IBSA Institut Biochimique SA · 1 drug in this class
  3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
  4. Pfizer · 1 drug in this class
  5. Rabin Medical Center · 1 drug in this class
  6. Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · 1 drug in this class
  7. Shijiazhuang Yiling Pharmaceutical Co. Ltd · 1 drug in this class
  8. Takeda · 1 drug in this class
  9. Thomas Jefferson University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diclofenac hydroxyethylpyrrolidine — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-hydroxyethylpyrrolidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: